We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor ... Aileron had previously raised money from Eli Lilly, Novartis and Roche ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Amphista Therapeutics appoints Paul Medeiros as Chief Business OfficerAppointment supports the Company’s ambitions to advance ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE ... In a 2-for-1 split, each share is turned into two new shares. This makes each share half the price, but the ...

Eli Lilly hopes that a new pill it's developing can do everything Ozempic can without the hassles. It's called orforglipron (put the emphasis on the second syllable: or-FOUR-glip-ron).

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...